|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TAF1 plays a critical role in AML1-ETO driven leukemogenesis.
|
31664040 |
2019 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among these AETFC components, HEB and E2A, two members of the ubiquitously expressed E proteins, directly interact with AML1-ETO, confer new DNA-binding capacity to AETFC, and are essential for leukemogenesis.
|
30593567 |
2019 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
AML1-ETO, the most common fusion oncoprotein by t (8;21) in acute myeloid leukaemia (AML), enhances hematopoietic self-renewal and leukemogenesis.
|
31119862 |
2019 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.
|
28381396 |
2017 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results indicate a feedback circuitry involving miR-9-1 and RUNX1-RUNX1T1, contributing to leukemogenesis in RUNX1-RUNX1T1 (+) AML cell lines.
|
27770540 |
2017 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data reveal that Asxl2 is a critical regulator of haematopoiesis and mediates transcriptional effects that promote leukemogenesis driven by AML1-ETO.
|
28516957 |
2017 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, there exists strong evidence that leukemic RUNX1-fusions such as RUNX1-ETO disrupt genomic integrity and induce a "mutator" phenotype during the early stages of leukemogenesis.
|
28299675 |
2017 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AML1-ETO promotes SIRT1 expression to enhance leukemogenesis of t(8;21) acute myeloid leukemia.
|
27725192 |
2017 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis.
|
28030795 |
2017 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, newer technologies like combining gene expression and DNA occupancy profiling assays, gene expression-based high-throughput screening, etc have led to identification of proteins or pathways that are required by AML1-ETO for leukemogenesis and the agents that modulate these proteins to be considered good candidates for targeted molecular therapy.
|
26563884 |
2016 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the genome-wide interplay between AML1/ETO and wild-type AML1 remains elusive in the leukemogenesis of t(8;21) AML.
|
26546158 |
2016 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While AML1-ETO prolongs survival and inhibits differentiation of hematopoietic stem cells (HSC), other contributory events are needed for cell proliferation and leukemogenesis.
|
27486062 |
2016 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified TET2 and PTPN11 mutations in both mouse and human AML and then demonstrated the ability of Tet2 loss and PTPN11 D61Y to initiate leukemogenesis in concert with expression of AML1-ETO in vivo.
|
26666262 |
2016 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GSEA analysis confirmed similar altered gene expression patterns in the truncated RUNX1 and RUNX1/ETO models, with both models showing alterations in genes involved in self-renewal and leukemogenesis, including homeobox genes, primitive erythroid genes and leukemogenic transcription factors.
|
25798834 |
2016 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.
|
25727291 |
2015 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We show in this study that both overexpression and knockout of microRNA (miR)-126 surprisingly result in enhanced leukemogenesis in cooperation with the t(8;21) fusion genes AML1-ETO/RUNX1-RUNX1T1 and AML1-ETO9a (a potent oncogenic isoform of AML1-ETO).
|
26361793 |
2015 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.
|
23645839 |
2013 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the role of AML1-ETO in leukemogenesis, we transfected the cloned AML1-ETO cDNA and expressed the AML1-ETO protein in U937 myelomonocytic leukemia cells.
|
23673926 |
2013 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since the expression of the fusion genes CBFB/MYH11 or RUNX1/RUNX1T1 alone is not sufficient to cause leukemia, we performed exome sequencing of an AML sample with an inv(16) to identify mutations, which may collaborate with the CBFB/MYH11 fusion during leukemogenesis.
|
23878140 |
2013 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both human and mouse models of AML have demonstrated that AML1-ETO is insufficient for leukemogenesis in the absence of secondary events.
|
22875638 |
2012 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.
|
22201794 |
2012 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).
|
20589720 |
2010 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Introduction of the mutation into AML1-ETO had minimal impact on in vivo leukemogenesis.
|
20708017 |
2010 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The contribution of activated c-Kit signaling to PML/RARalpha- and AML-1/ETO-induced leukemogenesis was investigated in a murine transduction/transplantation leukemia model.
|
19424569 |
2009 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further investigations on the potential in vivo effects of such a cleavage and its possible role in leukemogenesis would provide new insights for understanding the biology and treatment of AML1-ETO-associated leukemia.
|
17989718 |
2008 |